ReviewSensors (Basel, Switzerland)2026
Handwriting as a Biomarker for Early Detection of Parkinson's and Alzheimer's Diseases: A Comprehensive Guide for Researchers.
Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD) present a significant and growing challenge to the healthcare systems worldwide. Both conditions are progressive and often undetected early, making timely diagnosis crucial. Recently, breakthroughs in computer vision and artificial intelligence have enabled the development of non-invasive and cost-effective screening and decision-making tools, allowing for earlier detection of the disease. This review serves as a comprehensive guide, providing structured insights into computational research methods for automated detection of PD and AD, with focus on handwriting analysis as a subtle behavioral biomarker of neurological impairment. A range of methodologies is examined, including static and dynamic handwriting assessment, feature engineering procedures, deep learning and classical ML-based approaches. The analysis emphasizes the most effective methods, the handwriting features found to be most revealing, the datasets most used in the literature, and the performance levels reported for each disease. Several studies report that transfer learning based on convolutional neural networks and transformer-based architectures for Parkinson's disease diagnosis is regularly able to achieve high accuracy, frequently above 95% on benchmark datasets. In contrast, Alzheimer's disease research is progressively benefitting from multimodal approaches combining kinematic and spatial handwriting features to capture cognitive and motor changes. Structured summaries of publicly available handwriting datasets are provided, and critical advancements, ongoing challenges, and future research priorities are discussed. The integration of insights across the studies, through this work, aims to assist researchers and clinicians in the development and translation of handwriting-based, AI-guided diagnostic tools for neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.